NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference

Monday, March 15, 2010 General News J E 4
NEW YORK, March 15 NeoStem, Inc.(NYSE Amex: NBS) ("NeoStem" or the "Company"), an internationalbiopharmaceutical company with operations in the U.S. and China, announcedtoday a change for the Company's presentation at the Roth Capital Partners22nd Annual OC Growth Stock Conference scheduled for Monday, March 15, 2010.NeoStem's presentation will now take place at 10:30 a.m. Pacific Time.

The presentation venue is unchanged at the Ritz-Carlton, Laguna Niguel, atOne Ritz Carlton Dr, Dana Point, CA 92629.

Robin Smith, M.D., NeoStem's CEO and Chairman of the board of directors,will be available for one-on-one meetings with institutional investors at theconference. A copy of the investor presentation is being included in a Form8-K being filed with the Securities and Exchange Commission on March 15, 2010.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies,pursuit of anti-aging initiatives and building of a network of adult stem cellcollection centers in the U.S. and China that are focused on enabling peopleto donate and store their own (autologous) stem cells for their personal usein times of future medical need. The Company also has licensed various stemcell technologies, including a worldwide exclusive license to VSEL(TM)technology which uses very small embryonic-like stem cells, shown to haveseveral physical characteristics that are generally found in embryonic stemcells, and is pursuing the licensing of other technologies for therapeutic use.NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye,manufactures and distributes generic antibiotics in China. For moreinformation, please visit: .For more information, please contact: NeoStem, Inc. Robin Smith, CEO Phone: +1-212-584-4174 Email: Web: CCG Investor Relations, Inc. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: Web: Crocker Coulson, President Phone: +1-646-213-1915 Email:

SOURCE NeoStem, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
HIV Vaccine Strategy Expands Immune Responses
Allscripts to Announce Third Quarter Fiscal 2010 R...